P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: P1101 (Ropeginterferon alfa-2b); Drug: Nivolumab Sponsors: National Taiwan University Hospital; PharmaEssentia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research